Low dose IL-2

BIOLOGICAL2 trials

Sponsors

Iovance Biotherapeutics, Inc., AgonOx, Inc.

Conditions

Chronic Lymphocytic LeukemiaColorectal CancerGynecologic CancerHNSCCLung CancerMelanomaSmall Lymphocytic LymphomaUrogenital Cancer

Phase 1

Study of Autologous Peripheral Blood Lymphocytes in the Treatment of Patients With CLL or SLL

CompletedNCT04155710

Iovance Biotherapeutics, Inc.Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma

Start: 2020-02-19End: 2024-12-02Updated: 2025-12-24

Adoptive Cell Therapy Using Cancer Specific CD8+ Tumor Infiltrating Lymphocytes in Adult Patients With Solid Tumors

Active, not recruitingNCT05902520

AgonOx, Inc.Colorectal Cancer, Gynecologic Cancer, HNSCC +3

Start: 2023-06-19End: 2026-12-31Target: 18Updated: 2026-01-08

Related Papers

CD39+CD103+ selected CD8+ tumor infiltrating lymphocytes for the treatment of solid tumors 3905

The Journal of Immunology2025-11-01

Abstract LB067: Tumor-reactive CD8 TIL with an exhausted phenotype can be expanded and regress human tumors

Cancer Research2024-04-052 citations

Trial in Progress: Phase 1/2 Study Evaluating the Safety and Efficacy of Iov-2001, an Autologous, Non-Genetically Modified, Polyclonal T-Cell Product, in Patients with Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL) or Small Lymphocytic Lymphoma (SLL)

Blood2021-11-05

Abstract CT244: A Phase 1/2 study evaluating the safety and efficacy of IOV-2001 in patients with relapsed or refractory chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)

Cancer Research2021-07-01